FAKTOR-OPTIONSSCHEIN - ZEALAND PHARMA | Delayed Börse Stuttgart 10:21:44 27/05/2024 pm IST | ||
| 59.71 EUR | +8.19% |
|
| Current month | -4.72% | ||
| 1 month | -3.19% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ZEALAND PHARMA A/S
Latest news about ZEALAND PHARMA A/S
More news
| Date | Price | Change |
|---|---|---|
| 27/24/27 | 59.71 | +8.19% |
| 24/24/24 | 55.19 | -11.41% |
| 23/24/23 | 62.3 | +1.25% |
| 22/24/22 | 61.53 | -4.65% |
| 21/24/21 | 64.53 | +10.67% |
Delayed Quote Börse Stuttgart
Last update May 27, 2024 at 10:21 pm IST
More quotesStatic data
| Product type | Exotic Products |
|---|---|
| Buy / Sell | CALL |
| Underlying | ZEALAND PHARMA A/S |
| Issuer | Morgan Stanley |
| WKN | MB1CZL |
| ISIN | DE000MB1CZL0 |
| Date issued | 12/12/2022 |
| Strike | 308.6 kr |
| Maturity | Unlimited |
| Parity | 0.67 : 1 |
| Emission price | 10 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 94.34 € |
|---|---|
| Lowest since issue | 9.4 € |
| Spread | 1.19 € |
| Spread % | 1.94% |
Company Profile
Zealand Pharma A/S is specialized in the research and development of peptide drugs mainly for the treatment of diabetes, rare diseases and obesity.
At the end of 2022, the Group had a portfolio of 7 products in clinical development (including 2 in phase III, 3 in phase II and 2 in phase I), and 4 products in preclinical development.
Sector
-
Consensus: Zealand Pharma A/S
Sell
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
617
DKK
Average target price
785.6
DKK
Spread / Average Target
+27.32%
- Stock Market
- Certificates
- Certificat
